Intravitreal administration of bevacizumab in the treatment of choroidal metastasis in a patient with erlotinib-failed pulmonary adenocarcinoma.

Authors :: Lai CL
Fan KS
Lee YH
Chen HC
Fan WH
Source :: Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2012 Jun; Vol. 76 (3), pp. 496-8. Date of Electronic Publication: 2012 Apr 06.
Publication Year :: 2012
Abstract: Choroidal metastasis is uncommon and usually identified in a relatively advanced cancer status. The median survival after diagnosing choroid metastasis in lung cancer patients was only 1.9 months. Once failed to systemic treatment, there was no effective local treatment for saving visual acuity. The off-label use of intravitreal bevacizumab was popular in treating VEGF-mediated chorioretinal diseases worldwide. We here demonstrate a dramatic and durable response to intravitreal bevacizumab. Unlike the previous similar reports, our patient had failed both first- and second-line therapies.<br /> (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)

Subjects :: Aged
Angiogenesis Inhibitors administration & dosage
Antibodies, Monoclonal, Humanized administration & dosage
Bevacizumab
Choroid Neoplasms diagnosis
Humans
Intravitreal Injections
Male
Neoplasm Staging
Treatment Outcome
Adenocarcinoma pathology
Angiogenesis Inhibitors therapeutic use
Antibodies, Monoclonal, Humanized therapeutic use
Choroid Neoplasms drug therapy
Choroid Neoplasms secondary
Lung Neoplasms pathology

Full Text Access

Tools